(0.01%) 5 469.82 points
(0.13%) 39 164 points
(0.26%) 17 763 points
(0.07%) $80.89
(-5.04%) $2.62
(-0.80%) $2 312.20
(-0.11%) $28.84
(3.28%) $1 018.80
(0.35%) $0.936
(0.76%) $10.68
(0.50%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine...
Stats | |
---|---|
Šios dienos apimtis | 102 195 |
Vidutinė apimtis | 328 420 |
Rinkos kapitalizacija | 86.05M |
EPS | $-2.66 ( Q1 | 2024-05-06 ) |
Kita pelno data | ( $-0.970 ) 2024-09-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0.0500 (Sector) 42.63 (Industry) 0 |
ATR14 | $0.0570 (1.02%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-09 | Cr Group L.p. | Buy | 108 752 | Common Stock |
2024-05-09 | Cr Group L.p. | Buy | 1 716 048 | Common Stock |
2024-05-09 | Cr Group L.p. | Sell | 17 160 | Series A Preferred Stock |
2024-05-09 | Cr Group L.p. | Sell | 10 875 | Series B Preferred Stock |
2024-05-03 | Cr Group L.p. | Buy | 1 565 445 | Common Stock |
INSIDER POWER |
---|
12.46 |
Last 99 transactions |
Buy: 59 163 264 | Sell: 43 265 399 |
Tūris Koreliacija
T2 Biosystems Inc Koreliacija
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
CRDF | -0.808 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
T2 Biosystems Inc Koreliacija - Valiuta/Žaliavos
T2 Biosystems Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $7.19M |
Bruto pelnas: | $-8.83M (-122.74 %) |
EPS: | $-19.19 |
FY | 2023 |
Pajamos: | $7.19M |
Bruto pelnas: | $-8.83M (-122.74 %) |
EPS: | $-19.19 |
FY | 2022 |
Pajamos: | $22.31M |
Bruto pelnas: | $1.17M (5.23 %) |
EPS: | $-1 242.48 |
FY | 2021 |
Pajamos: | $28.06M |
Bruto pelnas: | $7.36M (26.21 %) |
EPS: | $-20.29 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
T2 Biosystems Inc
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.